

## Thyroid dysfunctions in morphoea: A preliminary report

Sir.

Morphoea is known to be associated with an increased incidence of autoimmune disorders and auto antibodies, so the coexistence of other autoimmune diseases is expected.<sup>[1]</sup> The association of thyroid dysfunction in morphoea has not yet been established and only a few studies and case reports are available in the literature.<sup>[2-6]</sup> This was the basis for our study to look for thyroid dysfunction in patients suffering from morphoea.

In this study, all histopathologically confirmed cases of morphoea were evaluated for thyroid dysfunction by history, clinical examination, and thyroid function tests. The normal range for TSH, T3 and T4 were taken as  $0.30-5.5 \mu IU/mL$ , 60-200 ng/dL, and 4.5-12 µg/dL respectively. Anti-thyroid peroxidase (anti-TPO) antibody testing and thyroid gland ultrasonography (USG) was done in a few patients with clinical features of thyroid dysfunction. If a patient had a TSH level of more than 5.5 µIU/mL, with no signs or symptoms of hypothyroidism, it was considered as subclinical hypothyroidism. Anti-TPO antibody testing was not done in all cases of subclinical hypothyroidism due to resource limitation. Fine needle aspiration cytology (FNAC) was done in patients with visible or palpable thyroid swelling.

The study involved 17 patients of morphoea which comprised of 15 (88.2%) females and 2 (11.8%) males, the female to male sex ratio being 7.5:1. Ten (58.8%) patients were in the age group of 21-40 years, four (23.5%) in the age group of less than 20 years, and three (17.7%) in the age group of 41-60 years. Plaque type morphoea was found in 14 (82.4%) patients, followed by 2 (11.8%) patients with linear morphoea and one (5.9%) patients with generalized morphoea. The duration of disease ranged from 1 month to 10 years, with an average duration of 2.48 years [Table 1].

TSH levels were elevated in 7 (41.2%) patients, and all cases had normal values for T3, T4, anti-TPO antibodies, USG and FNAC. All the patients with

Table 1: Clinical, laboratory and epidemiological parameters in morphoea patients

	Males	Females	Total
Age group			
<20 years	1	3	4
21-40 years	1	9	10
41-60 years	0	3	3
Total	2	15	17
Type of morphoea			
Plaque	2	12	14
Linear	0	2	2
Generalized	0	1	1
Total	2	15	17
Abnormal thyroid function tests			
Elevated TSH*	0	7	7
Duration of disease			
Maximum: 10 years; Minimum: 1 month; Average 2.48 years			

\*TSH: Thyroid stimulating hormone

abnormal TSH were females and were diagnosed to have subclinical hypothyroidism as they were asymptomatic. Six patients had plaque type morphoea and one had generalized morphoea. The two patients who suffered from linear morphoea had normal thyroid functions.

Morphoea is a connective tissue disease associated with sclerosis of the skin. It may be localized or generalized. The etiology and precise mechanisms that trigger the cascade of molecular events that culminate in skin fibrosis is not clearly understood. Many inflammatory and immunologic pathways are ultimately responsible for the vascular changes, increased collagen production and extracellular matrix proliferation. It is proposed that endothelial cell damage may represent the initial and pivotal step in the development of soft tissue change in morphoea.

There are many clinical subtypes of localized morphoea, which include plaque, profundus, bullous, linear, frontoparietal, segmental, and guttate type. Plaque type morphoea is the commonest subtype.<sup>[7]</sup> In our study, plaque type of morphoea was the commonest, followed

How to cite this article: Hassan I, Arif T, Anwar P. Thyroid dysfunctions in morphoea: A preliminary report. Indian J Dermatol Venereol Leprol 2014;80:579.

Received: November, 2013. Accepted: March, 2014. Source of Support: Nil. Conflict of Interest: None declared.

by linear and generalized morphoea. The peak age of incidence is 20-40 years, [8] which was similar to our study. The female to male ratio is 3:1 in many studies, [8,9] although our study recorded it at 7.5:1.

Morphoea is an immunological disorder and it may be associated with other autoimmune disorders. Organ specific auto-antibodies have been found to be more common in patients with morphoea than in controls. The coexistence of two autoimmune diseases may not occur by chance, but could be attributed to autoimmune reactions elicited by the recognition of common antigens.

Autoimmune thyroid diseases are one of the most common endocrine disorders. Hashimoto`s thyroiditis is a T-cell mediated organ specific autoimmune disease, that results in clinical hypothyroidism due to thyroid destruction which is mediated by infiltrating and locally activated thyroglobulin specific T-cells. Grave`s disease is characterised by hyperthyroidism due to excessive production of thyroid hormones induced by thyrpotropin receptor specific autoantibodies.

Demonstration of thyroid antibodies is essential for the evaluation of association between morphoea and autoimmune thyroid disease, and not merely on the basis of T3, T4 and TSH abnormalities. Thyroid antibodies were found to be within normal limits in our patients. In this study, abnormal thyroid function in the form of elevated TSH was found in 41.2% patients. It may just be a coincidental finding as the normal population can also show abnormal thyroid function. In conclusion, the abnormal thyroid function tests observed in patients of morphoea in our study should be considered a preliminary finding and further studies may be undertaken to detect or refute a definite association.

## Iffat Hassan, Tasleem Arif, Parvaiz Anwar

Department of Dermatology, Sexually Transmitted Diseases and Leprosy, Government Medical College, University of Kashmir, Srinagar, Jammu and Kashmir, India Address for correspondence: Prof. Iffat Hassan, Department of Dermatology, Sexually Transmitted Diseases and Leprosy, Government Medical College Srinagar, University of Kashmir, Jammu and Kashmir, India.

E-mail: hassaniffat@gmail.com

## **REFERENCES**

- Harrington CI, Dunsmore IR. An investigation into the incidence of auto-immune disorders in patients with localized morphoea. Br J Dermatol 1989;120:645-8.
- Horita M, Takahashi N, Seike M, Nasu S, Takaki R. A case of primary biliary cirrhosis associated with Hashimoto'sthyroiditis, scleroderma and Sjögren's syndrome. Intern Med 1992;31:418-21.
- Claudy AL, Segault D, Rousset H, Moulin G. Facial hemiatrophy, homolateral cervical linear scleroderma and thyroid disease. Ann DermatolVenereol 1992;119:543-5.
- Ghayad E, Tohme A, Haddad F, Haddad C, Choueiry R. Scleroderma with anomalies of the thyroid functions, 7 cases. Ann Med Interne (Paris) 1997;148:307-10.
- Lee HJ, Kim MY, Ha SJ, Kim JW. Two cases of morphea associated with Hashimoto'sthyroiditis. ActaDermVenereol 2002;82:58-9.
- Hiremath NC, Madan Mohan NT, Srinivas C, Sangolli PM, Srinivas K, Vrushali VD.Juvenile localized scleroderma with autoimmune thyroid disorder.Indian J Dermatol 2010;55:308-9.
- Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo ClinProc 1995:70:1068-76.
- Peterson LS, Nelson AM, Su WP, Mason T, O'Fallon WM, Gabriel SE. The epidemiology of morphoea (localized scleroderma) in Olmsted County 1960-1993. J Rheumatol 1997;24:73-80.
- Christianson HB, Dorsey CS, Kierland RR, O'learyPA. Localized scleroderma; a clinical study of two hundred thirty-five cases. AMA Arch Derm 1956;74:629-39.
- Delamere JP, Scott DL, Felix-Davies DD. Thyroid dysfunction and rheumatic diseases. JR Soc Med 1982;75:102-6.
- 11. Innocencio RM, Romaldini JH, Ward LS. Thyroid autoantibodies in autoimmune diseases. Medicina (B Aires) 2004;64:227-30.

Access this article online		
Quick Response Code:	Website: www.ijdvl.com	
	<b>DOI:</b> 10.4103/0378-6323.144230	